Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis
ALK TKIs have different safety profiles regarding lung toxicity, which normally occurs within the first 2 months. Administration in combination with PPIs, amlodipine, and magnesium oxide significantly increases the risk of ILD. These results provide risk prediction for ILD related to ALK TKIs and support pharmacovigilance to promote safe prescribing in oncology.
Authors
- Shaohui Zhang (ORCID: https://orcid.org/0000-0003-4371-7039)
- Lulu Li (ORCID: https://orcid.org/0000-0002-7526-5789)
- Junli Dong (ORCID: https://orcid.org/0000-0003-3728-875X)
- Tiying Deng
- Minyu Zhong
- Haibin Song (ORCID: https://orcid.org/0009-0002-0585-1114)
Institutions
- Wuhan No.1 Hospital (CN)
- Wuhan No.9 Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3389/fphar.2024.1361443
- Citations
- 12
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 5.03